Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · IEX Real-Time Price · USD
15.96
-0.46 (-2.80%)
At close: Jul 19, 2024, 4:00 PM
16.01
+0.05 (0.31%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Burke T. Barrett |
Contact Details
Address: 3957 Point Eden Way Hayward, California 94545 United States | |
| Phone | 510-906-4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kevin P. Danahy | President and Chief Executive Officer |
| Robert W. Duggan | Executive Chairman |
| Darrin R. Uecker | Chief Technology Officer and Director |
| Mitchell E. Levinson | Chief Strategy Officer |
| Dr. Richard Nuccitelli Ph.D. | Chief Science Officer |
| Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
| Patty Perla | Vice President of Human Resources |
| David Danitz | Senior Vice President of Engineering |
| Dr. Gansevoort Dunnington M.D. | Chief Medical Officer |
| Dr. Niv Ad M.D. | Chief Science Officer of Cardiac Surgery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | 8-K | Current Report |
| Jul 15, 2024 | 424B5 | Filing |
| Jul 15, 2024 | S-3MEF | Filing |
| Jul 8, 2024 | 8-K | Current Report |
| Jul 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 424B2 | Prospectus |
| Jun 4, 2024 | 8-K | Current Report |